AT&T Slumps on Legal Blow and Satellite Threat Ahead of SpaceX IPO
Markets Daniel Marsh

AT&T Slumps on Legal Blow and Satellite Threat Ahead of SpaceX IPO

AT&T shares fell 3.3% after a Supreme Court setback and an Oppenheimer downgrade warning of satellite broadband competition from SpaceX, whose IPO nears.

T TMUS VZ
Marvell Surges on S&P 500 Speculation, AI Demand; After-Hours Pullback
Markets Daniel Marsh

Marvell Surges on S&P 500 Speculation, AI Demand; After-Hours Pullback

Marvell Technology surged 4.9% on S&P 500 inclusion bets and AI demand, bucking a chip selloff. Shares later pulled back after hours, with volume more than double average.

MRVL AVGO NVDA AMD MU QCOM SPY
Guidewire Stock Drops Despite Earnings Beat as ARR Guidance Disappoints
Earnings James Calloway

Guidewire Stock Drops Despite Earnings Beat as ARR Guidance Disappoints

Guidewire Software shares plunged 13.77% after hours as investors focused on a narrow miss in annual recurring revenue guidance, despite the company beating earnings and revenue estimates.

GWRE
Verizon Stock Falls on Supreme Court Ruling Despite Dividend Assurance
Regulation James Calloway

Verizon Stock Falls on Supreme Court Ruling Despite Dividend Assurance

Verizon shares fell 3.8% due to a Supreme Court ruling against wireless carriers over FCC fines, despite a reaffirmed dividend. The stock's 6.3% yield draws income investors, but regulatory and debt challenges persist.

VZ T TMUS
Fidelity Opens SpaceX IPO to Retail Investors with $2,000 Minimum
IPO Michael Okonkwo

Fidelity Opens SpaceX IPO to Retail Investors with $2,000 Minimum

Fidelity slashes IPO access minimum to $2,000 for SpaceX, reserving up to 30% for retail investors. Allocations are set for June 12, but demand may outstrip supply and volatility is warned.

SPY QQQ
BlackBerry Shares Surge on QNX Software Momentum Ahead of Earnings
Technology Sarah Chen

BlackBerry Shares Surge on QNX Software Momentum Ahead of Earnings

BlackBerry shares climbed 1.4% to $10.34, approaching a 52-week high, as QNX software gains traction in robotics and physical AI. The next key catalyst is the June 25 earnings report.

BB
Nokia Stock Plunges 6% as AI Rally Fades, Nordea Boosts Target
Markets Daniel Marsh

Nokia Stock Plunges 6% as AI Rally Fades, Nordea Boosts Target

Nokia shares fell 6.15% in Helsinki, snapping a three-day AI rally, as investors questioned pricing of AI and Nvidia deals, despite Nordea raising its price target to €15.70.

NVDA CIEN
Samsara Shares Dip Despite Q1 Beat as Tepid Guidance Tempers Enthusiasm
Earnings James Calloway

Samsara Shares Dip Despite Q1 Beat as Tepid Guidance Tempers Enthusiasm

Samsara shares declined after the company beat Q1 estimates but issued Q2 guidance that barely exceeded forecasts, raising concerns about limited upside despite strong ARR and cash flow.

IOT
DocuSign Stock Dips Despite Strong Q1 Results as AI Growth Concerns Linger
Earnings James Calloway

DocuSign Stock Dips Despite Strong Q1 Results as AI Growth Concerns Linger

DocuSign shares fell 4.2% after hours despite a Q1 earnings and revenue beat, as near-consensus guidance fueled doubts about the pace of AI-driven growth.

DOCU
US Mortgage Rates Edge Down but Buyer Demand Remains Tepid
Economy Daniel Marsh

US Mortgage Rates Edge Down but Buyer Demand Remains Tepid

Despite a slight dip in mortgage rates to 6.48%, homebuyer activity remains subdued, with mortgage applications falling 2.5% and list prices dropping 2.4% year-over-year.

SPY
T1 Energy Hits 52-Week High on $32M KORE Power Acquisition
Markets Daniel Marsh

T1 Energy Hits 52-Week High on $32M KORE Power Acquisition

T1 Energy shares hit a 52-week high after agreeing to buy KORE Power for $32 million, moving into battery storage and AI data center power.

FSLR ENPH SEDG
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Markets Daniel Marsh

Merck Shares Jump as New Drug Data Eases Keytruda Concerns

Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.

MRK UNH BMY GILD AZN SNY